Tradipitant for COVID-19: real-time analysis

Download Image

Post

c19early.org

Tradipitant for COVID-19

1 study with 145 patients

Serious outcome risk

Tradipitant

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Tradipitant studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−36%

Mortality (1)−36%

RCTs (1)−36%

Late (1)−36%

00.511.5+

← Tradipitant
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Tradipitant is an oral small-molecule neurokinin-1 receptor antagonist that blocks substance P signalling, potentially reducing neurogenic pulmonary inflammation.


Apr 1 2024	Polymeropoulos et al., NCT04326426	ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection
Apr 1 2024	36% higher mortality (p=0.41) and no change in improvement. RCT 145 severe/critical COVID-19 patients in the USA, showing no significant difference with tradipitant treatment.